Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer

Andrew V Schally, Jorg Engel

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

This chapter discusses the development of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH), also known as GnRH, and their clinical uses. Specific receptors for LHRH were first detected on human breast, prostatic, ovarian, endometrial, and pancreatic cancers. Clinical applications of LHRH agonists are based on gradual down-regulation of pituitary receptors for LHRH and inhibition of the pituitary and gonads. LHRH antagonists represent another class of compounds that may be useful for treatment of sex-hormone dependent cancers and various gynecological applications. LHRH antagonists produce an immediate suppression of the secretion of gonadotrophins and sex steroids and thus achieve rapid therapeutic effects. LHRH agonists and antagonists can be used for the treatment of endometriosis, uterine leiomyomas, and in assisted reproduction programs. The preferred primary treatment of advanced androgen-dependent prostate cancer is based on the periodic administration of depot preparations of LHRH agonists. LHRH agonists can be likewise applied for treatment of breast cancer. LHRH antagonists have been successfully tried for therapy of prostate cancer and benign prostatic hypertrophy. Cytotoxic analogs of LHRH AN-152 and AN-207 containing doxorubicin or 2-pyrrolinodoxorubicin that can be targeted to LHRH receptors on tumors have been synthesized and successfully tested in in-vivo experimental cancer models of human prostate, breast, ovarian, and endometrial cancers, and renal cell carcinomas, melanomas, and lymphomas.

Original languageEnglish
Title of host publicationHandbook of Biologically Active Peptides
PublisherElsevier Inc.
Pages421-427
Number of pages7
ISBN (Print)9780123694423
DOIs
StatePublished - Dec 1 2006

Fingerprint

Gonadotropin-Releasing Hormone
Hormone Antagonists
Neoplasms
LHRH Receptors
Prostatic Neoplasms
Endometrial Neoplasms
Breast Neoplasms
Ovarian Neoplasms
Delayed-Action Preparations
Therapeutics
Gonadal Steroid Hormones
Gonadotropins
Prostatic Hyperplasia
Gonads
Leiomyoma
Therapeutic Uses
Endometriosis
Doxorubicin
Androgens
Pancreatic Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Schally, A. V., & Engel, J. (2006). Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer. In Handbook of Biologically Active Peptides (pp. 421-427). Elsevier Inc.. https://doi.org/10.1016/B978-012369442-3/50063-5

Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer. / Schally, Andrew V; Engel, Jorg.

Handbook of Biologically Active Peptides. Elsevier Inc., 2006. p. 421-427.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schally, AV & Engel, J 2006, Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer. in Handbook of Biologically Active Peptides. Elsevier Inc., pp. 421-427. https://doi.org/10.1016/B978-012369442-3/50063-5
Schally AV, Engel J. Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer. In Handbook of Biologically Active Peptides. Elsevier Inc. 2006. p. 421-427 https://doi.org/10.1016/B978-012369442-3/50063-5
Schally, Andrew V ; Engel, Jorg. / Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer. Handbook of Biologically Active Peptides. Elsevier Inc., 2006. pp. 421-427
@inbook{3833dfd8e39547bcb6affa9feebfc557,
title = "Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer",
abstract = "This chapter discusses the development of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH), also known as GnRH, and their clinical uses. Specific receptors for LHRH were first detected on human breast, prostatic, ovarian, endometrial, and pancreatic cancers. Clinical applications of LHRH agonists are based on gradual down-regulation of pituitary receptors for LHRH and inhibition of the pituitary and gonads. LHRH antagonists represent another class of compounds that may be useful for treatment of sex-hormone dependent cancers and various gynecological applications. LHRH antagonists produce an immediate suppression of the secretion of gonadotrophins and sex steroids and thus achieve rapid therapeutic effects. LHRH agonists and antagonists can be used for the treatment of endometriosis, uterine leiomyomas, and in assisted reproduction programs. The preferred primary treatment of advanced androgen-dependent prostate cancer is based on the periodic administration of depot preparations of LHRH agonists. LHRH agonists can be likewise applied for treatment of breast cancer. LHRH antagonists have been successfully tried for therapy of prostate cancer and benign prostatic hypertrophy. Cytotoxic analogs of LHRH AN-152 and AN-207 containing doxorubicin or 2-pyrrolinodoxorubicin that can be targeted to LHRH receptors on tumors have been synthesized and successfully tested in in-vivo experimental cancer models of human prostate, breast, ovarian, and endometrial cancers, and renal cell carcinomas, melanomas, and lymphomas.",
author = "Schally, {Andrew V} and Jorg Engel",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/B978-012369442-3/50063-5",
language = "English",
isbn = "9780123694423",
pages = "421--427",
booktitle = "Handbook of Biologically Active Peptides",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Analogs of Luteinizing Hormone-Releasing Hormone (lhrh) in Cancer

AU - Schally, Andrew V

AU - Engel, Jorg

PY - 2006/12/1

Y1 - 2006/12/1

N2 - This chapter discusses the development of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH), also known as GnRH, and their clinical uses. Specific receptors for LHRH were first detected on human breast, prostatic, ovarian, endometrial, and pancreatic cancers. Clinical applications of LHRH agonists are based on gradual down-regulation of pituitary receptors for LHRH and inhibition of the pituitary and gonads. LHRH antagonists represent another class of compounds that may be useful for treatment of sex-hormone dependent cancers and various gynecological applications. LHRH antagonists produce an immediate suppression of the secretion of gonadotrophins and sex steroids and thus achieve rapid therapeutic effects. LHRH agonists and antagonists can be used for the treatment of endometriosis, uterine leiomyomas, and in assisted reproduction programs. The preferred primary treatment of advanced androgen-dependent prostate cancer is based on the periodic administration of depot preparations of LHRH agonists. LHRH agonists can be likewise applied for treatment of breast cancer. LHRH antagonists have been successfully tried for therapy of prostate cancer and benign prostatic hypertrophy. Cytotoxic analogs of LHRH AN-152 and AN-207 containing doxorubicin or 2-pyrrolinodoxorubicin that can be targeted to LHRH receptors on tumors have been synthesized and successfully tested in in-vivo experimental cancer models of human prostate, breast, ovarian, and endometrial cancers, and renal cell carcinomas, melanomas, and lymphomas.

AB - This chapter discusses the development of agonists and antagonists of luteinizing hormone-releasing hormone (LHRH), also known as GnRH, and their clinical uses. Specific receptors for LHRH were first detected on human breast, prostatic, ovarian, endometrial, and pancreatic cancers. Clinical applications of LHRH agonists are based on gradual down-regulation of pituitary receptors for LHRH and inhibition of the pituitary and gonads. LHRH antagonists represent another class of compounds that may be useful for treatment of sex-hormone dependent cancers and various gynecological applications. LHRH antagonists produce an immediate suppression of the secretion of gonadotrophins and sex steroids and thus achieve rapid therapeutic effects. LHRH agonists and antagonists can be used for the treatment of endometriosis, uterine leiomyomas, and in assisted reproduction programs. The preferred primary treatment of advanced androgen-dependent prostate cancer is based on the periodic administration of depot preparations of LHRH agonists. LHRH agonists can be likewise applied for treatment of breast cancer. LHRH antagonists have been successfully tried for therapy of prostate cancer and benign prostatic hypertrophy. Cytotoxic analogs of LHRH AN-152 and AN-207 containing doxorubicin or 2-pyrrolinodoxorubicin that can be targeted to LHRH receptors on tumors have been synthesized and successfully tested in in-vivo experimental cancer models of human prostate, breast, ovarian, and endometrial cancers, and renal cell carcinomas, melanomas, and lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=84882925846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882925846&partnerID=8YFLogxK

U2 - 10.1016/B978-012369442-3/50063-5

DO - 10.1016/B978-012369442-3/50063-5

M3 - Chapter

SN - 9780123694423

SP - 421

EP - 427

BT - Handbook of Biologically Active Peptides

PB - Elsevier Inc.

ER -